enGene Therapeutics Inc. Shareholders' Equity
enGene Therapeutics Inc. (ENGN) had Shareholders' Equity of $230.29 million as of 2026-07-31, per its 10-Q filed 2026-09-08.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-09-08
- 2026-07-31: Stockholders' Equity Attributable to Parent $230.29M.
- 2026-04-30: Stockholders' Equity Attributable to Parent $255.17M.
- 2026-01-31: Stockholders' Equity Attributable to Parent $281.55M.
- 2025-10-31: Stockholders' Equity Attributable to Parent $167.71M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-07-31 | $230.29M 10-Q · filed 2026-09-08 |
| 2026-04-30 | $255.17M 10-Q · filed 2026-09-08 |
| 2026-01-31 | $281.55M 10-Q · filed 2026-09-08 |
| 2025-10-31 | $167.71M 10-Q · filed 2026-09-08 |
| 2025-07-31 | $200.67M 10-Q · filed 2026-09-08 |
| 2025-04-30 | $227.29M 10-Q · filed 2026-09-08 |
| 2025-01-31 | $249.95M 10-Q · filed 2026-09-08 |
| 2024-10-31 | $272.61M 10-Q · filed 2026-09-08 |
| 2024-07-31 | $230.33M 10-Q · filed 2025-09-11 |
| 2024-04-30 | $242.97M 10-Q · filed 2025-09-11 |
| 2024-01-31 | $62.38M 10-Q · filed 2025-09-11 |
| 2023-10-31 | $72.49M 10-K · filed 2025-12-22 |
| 2023-07-31 | -$93.92M 10-Q · filed 2024-09-10 |
| 2023-04-30 | -$89.24M 10-Q · filed 2024-09-10 |
| 2023-01-31 | -$84.01M 10-Q · filed 2024-09-10 |
| 2022-10-31 | -$76.61M 10-K · filed 2024-12-19 |
| 2021-10-31 | -$53.44M 10-K · filed 2024-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |